<DOC>
	<DOCNO>NCT01592019</DOCNO>
	<brief_summary>The investigator hypothesize technique call microdialysis use measure amount drug diclofenac penetrates ( enters ) fatty tissue skin . Microdialysis use small device call 'probe ' determine amount drug enters body tissue . The small device place directly fatty tissue sample take specific time . The investigator determine whether site application affect availability drug .</brief_summary>
	<brief_title>Clinical Study Evaluate Role Microdialysis Comparison Topical Products</brief_title>
	<detailed_description />
	<mesh_term>Diclofenac hydroxyethylpyrrolidine</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Males female , 18 55 year age . Body mass index 18.5 32 kg/m2 , inclusive . Nonsmoker ( smoke 12 month prior screen ) . Healthy basis physical examination , medical history , vital sign . Healthy basis clinical laboratory test perform screen . If result serum chemistry panel ( include liver enzymes , specific test ) hematology outside normal reference range , subject may include study physician judge abnormality deviation normal clinically significant . Female subject must postmenopausal ( least 6 month ) , surgically sterile , abstinent ; , childbearing potential sexually active , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch ) entry throughout study . Also , subject must negative serum human chorionic gonadotropin pregnancy test initial screening . Agree consume alcohol 72 hour prior application study patch discharge unit . Agree use diclofenaccontaining medication enrol study . Willing adhere prohibition restriction specify protocol . Subjects must sign informed consent document indicate understand purpose procedure require study willing participate study . Subjects willing shower use soap/cleansers screen visit end study , namely Oil Olay Moisturizing Bar Soaps Shea Butter . Subjects willing avoid use body oil , cream , lotion , powder test area period 48 hour application patch . Clinically significant abnormal value hematology chemistry screening . History current significant medical illness include ( limited ) cardiovascular thrombotic event , myocardial infarction , stroke cardiac disease , hypertension , peptic ulcer disease gastrointestinal bleeding , skin disorder , hematological disease , bronchospastic respiratory disease , asthma , diabetes mellitus , renal hepatic insufficiency , illness investigator considers exclude subject . History atopic eczema , dry skin ichthyosis . Excessive hair site application could possibly affect drug absorption ; scar tissue , open tissue ( ) , tattoo coloration would interfere test site , assessment , reaction drug , may compromise safety subject . Known allergies hypersensitivity FlectorÂ® Patch diclofenaccontaining product . Clinically significant abnormal physical examination and/or vital sign ( e.g . systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg , heart rate &gt; 100 bpm &lt; 45 bpm ) . Received investigational drug ( include vaccine ) within 60 day prior study drug administration currently enrol investigational study . Pregnant breastfeeding . Recent history surgery ; within past 3 month prior screen . Clinically significant acute illness within 7 day prior study drug administration . Donation 1 unit ( approximately 450 mL ) blood acute loss equivalent amount blood within 60 day prior study drug administration . Any condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement . Employees investigator study center , direct involvement propose study study direction investigator study center , well family member employee investigator . Overthecounter prescription use nonsteroidal antiinflammatory drug product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>